Notice: Update on the Distribution to Court approved Class Members.
The Court has approved the distribution of the net settlement funds to eligible Court-approved Claimants who qualified for an award under the Plan of Allocation. A distribution of funds has occurred on the following date:
January 2020
If you submitted a Claim in this case and have any questions related to that Claim, please contact the Claims Administrator whose contact information is listed here below:
Allergan Proxy Violation Securities Litigation
P.O. Box 10436
Dublin, OH 43017-4036
(855) 474-3851
Overview
WELCOME TO THE ALLERGAN PROXY VIOLATION SECURITIES LITIGATION WEBSITE
The information contained on this web page is only a summary of the information presented in more detail in the Notice of (I) Proposed Settlement and Plan of Allocation; (II) Settlement Fairness Hearing; and (III) Motion for an Award of Attorneys’ Fees and Reimbursement of Litigation Expenses (the “Settlement Notice”). Because this website is just a summary, you should review the Settlement Notice for additional details.
This Action was brought on behalf of a class of investors who sold Allergan, Inc. common stock during the period from February 25, 2014 through April 21, 2014, inclusive (“Class Period”) against defendants Valeant Pharmaceuticals International, Inc., Valeant Pharmaceuticals International, and J. Michael Pearson (the “Valeant Defendants”) and Pershing Square Capital Management, L.P., PS Management GP, LLC, PS Fund 1, LLC, Pershing Square, L.P., Pershing Square II, L.P., Pershing Square GP, LLC, Pershing Square Holdings, Ltd., Pershing Square International, Ltd., and William Ackman (the “Pershing Defendants”). The Action alleges that the Valeant Defendants tipped the Pershing Defendants to its contemplated takeover attempt of Allergan, and that the Pershing Defendants bought Allergan stock during the Class Period based on that information, violating federal securities laws prohibiting insider trading.
The Court-appointed representatives for the Court-certified Class, State Teachers Retirement System of Ohio, Iowa Public Employees Retirement System, and Patrick T. Johnson, on behalf of themselves and the other members of the Class, have reached a settlement with Defendants for $250,000,000 in cash that resolves all claims in the Action (the “Settlement”).
On June 12, 2018, the Court held a hearing to consider final approval of the Settlement and related matters. On August 14, 2018, the Court entered a Judgment approving the Settlement as fair, reasonable and adequate, entered an order approving the Plan of Allocation for the proceeds of the Settlement, and entered an order awarding attorneys’ fees and reimbursement of litigation expenses.
The Class consists of:
All persons who sold Allergan common stock on any trading day during the period February 25, 2014 through April 21, 2014, inclusive, and were damaged thereby.
For the full definition of the Class, including persons and entities excluded from the Class, please read the Settlement Notice. Persons who traded securities other than Allergan common stock, including derivative securities with a value that is a function of or related to the value of Allergan common stock (“Allergan Derivative Securities”), are not members of the Class as a consequence of those trades. A separate settlement has been reached on behalf of traders in Allergan Derivative Securities. For information about that settlement please visit: www.AllerganDerivativesSettlement.com.
Please read the Settlement Notice to fully understand your rights and options.
The claims filing deadline passed on August 7, 2018.
On January 31, 2020, the initial distribution occurred, and payments were made to Court approved Class Members.